Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.

BICAMS suitable for measuring cognition during multiple sclerosis relapse

10 Jun 2018
Multiple Sclerosis (MS) is a debilitating disease, in which nerve damage affects communications between the brain and body. HSCT could provide the therapeutic answer for MS patients.

Use of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is suitable for a quick assessment of patient cognition during multiple sclerosis (MS) relapse, a recent study has shown.

The study included 120 MS patients (60 with relapsing and 30 with stable disease) and 30 healthy controls. All groups were matched according to demographic and disease characteristics.

Relapsing and stable MS patients consistently had lower mean BICAMS scores than healthy controls: Symbol Digit Modalities Test (SDMT; 40.18±11.42 and 46.60±11.54 vs 53.83±8.91; p<0.001), Brief Visuospatial Memory Test-Revised (BVMT-R; 22.57±6.07 and 25.23±5.66 vs 29.03±4.22; p<0.001) and California Verbal Learning Test, II edition (CVLT-II; 52.02±9.61 and 54.80±9.40 vs 66.97±4.68; p<0.001).

Scores during relapse and 1 and 3 months after relapse were then compared. Scores were significantly higher 1 month after relapse (SDMT: 46.20±12.28; BVMT-R: 26.30±4.56; CVLT-II: 58.45±8.36). Only scores in the CVLT-II showed further significant improvement between 1 and 3 months.

“Assessing the results after relapse, we found that the results of all of the tests were significantly higher at 1 month after relapse than during relapse and that the results of only the verbal memory test were significantly higher at 3 months after relapse than after 1 month,” said researchers.

“Neuropsychological assessment, like physical disability assessment, is important during relapse. BICAMS may be suitable for quick and effective assessment of cognition during relapse,” they added.

For the study, MS patients were eligible for inclusion if they had not been assessed with BICAMS in the past and if they were not taking medications that may affect cognition. One-way analysis of variance was used to compare the means among the three patient groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.